Monitor for future clinical updates, patent approvals, or partnership expansions; current announcement is speculative and lacks near-term commercial catalysts.
Price Chart
Executive Summary
SciSparc Ltd. announced that NeuroThera Labs, in which it holds a 75% stake, has filed a patent application in Hong Kong with Clearmind Medicine for a novel MEAI-PEA combination therapy targeting major depressive disorder. The filing highlights a potential non-hallucinogenic, neuroplastogenic treatment, but no clinical data, financial terms, or commercial timelines were provided.
Key Facts
- SciSparc holds ~75% controlling interest in NeuroThera Labs Inc. (TSXV: NTLX).
- Patent application filed in Hong Kong by Clearmind Medicine for a combination therapy of MEAI (from Clearmind) and PEA (from NeuroThera) to treat major depressive disorder (MDD).
- No clinical trial results, revenue projections, or financial details disclosed.
- Therapy described as non-hallucinogenic and potentially safer/affordable vs. SSRIs, but remains pre-commercial and speculative.
- Forward-looking statements include risks related to development, regulatory approval, and market competition.
Financial Impact
No immediate financial impact — early-stage IP development with no disclosed funding, milestones, or revenue potential.
Risk Factors
- No guarantee the patent will be granted or provide meaningful IP protection.
- Therapy is pre-clinical — significant regulatory and development risks remain.
- SciSparc’s market cap is very small ($2M), increasing volatility and liquidity risk.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3256253 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 26, 2026 1d ago | 6-K | $1.29 | awaiting T+5 | — | $0.8500 (+34.08%) |
Oct 23, 2026 4d ago | 6-K | $1.09 | awaiting T+5 | — | $0.8500 (−22.02%) |
Oct 22, 2026 5d ago | Press Release | $1.20 | awaiting T+5 | — | $0.8500 (−29.17%) |
Oct 15, 2026 12d ago | 6-K | $2.00 $1.20 | ▲ +40.00% | ▲ +38.99% | $0.8500 (+57.50%) |
Oct 15, 2026 12d ago | 6-K | $2.00 $1.20 | ▼ −40.00% | ▼ −38.99% | $0.8500 (−57.50%) |
Oct 15, 2026 12d ago | Press Release | $2.00 $1.20 | ▼ −40.00% | ▼ −38.99% | $0.8500 (−57.50%) |
Oct 7, 2026 20d ago | 6-K | $4.64 $3.63 | ▼ −21.77% | ▼ −20.79% | $0.8500 (−81.68%) |
Sep 30, 2026 27d ago | 6-K | $4.55 $4.43 | ▲ +2.64% | ▲ +3.94% | $0.8500 (+81.32%) |
Sep 24, 2026 4w ago | 6-K | $5.39 $4.55 | ▼ −15.58% | ▼ −15.17% | $0.8500 (−84.23%) |
Sep 23, 2026 4w ago | Press Release | $5.01 $4.72 | ▼ −5.79% | ▼ −5.11% | $0.8500 (−83.03%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers